<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314273</url>
  </required_header>
  <id_info>
    <org_study_id>TBK-10-01</org_study_id>
    <nct_id>NCT02314273</nct_id>
  </id_info>
  <brief_title>Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL</brief_title>
  <official_title>Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Children's Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find out if rhIL-11（Interleukin 11） may
      increase the platelet count in Childhood patients with acute lymphocytic leukemia (ALL) who
      develop low platelet counts while receiving standard CAT（cyclophosphamide+Cytosine
      arabinoside+mercaptopurine，7d） therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group A：patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a
      day for 10 days or until platelet count ≥80,000/mL Group B：control group
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>platelet infusion</measure>
    <time_frame>14 days</time_frame>
    <description>frequency of platelet infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemorrhagic tendency</measure>
    <time_frame>14 days</time_frame>
    <description>conditions of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infection</measure>
    <time_frame>14 days</time_frame>
    <description>incident of infection during 14d after chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission rate</measure>
    <time_frame>14 days</time_frame>
    <description>remission rate during 14d after chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet Count</measure>
    <time_frame>14 days</time_frame>
    <description>recovery of peripheral platelet count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Pancytopenia Due to Chemotherapy</condition>
  <arm_group>
    <arm_group_label>rhIL-11 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhIL-11</intervention_name>
    <description>patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL</description>
    <arm_group_label>rhIL-11 group</arm_group_label>
    <other_name>Recombinant Human Interleukin-11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  new diagnosis of ALL

          -  TBIL≤34umol/L，Cr≤120umol/L，a normal EF

          -  age ＜18 years

        Exclusion Criteria:

          -  patients with uncontrolled infection

          -  patients with Acute congestive heart failure or chronicity cardiorespiratory
             functional defect or serious cardiac arrhythmias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tang Jingyan, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Children's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Children's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soochow University Affiliated Children's Hospital</name>
      <address>
        <city>Soochow</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oprelvekin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

